|
Aug 6
|
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
|
|
Jul 31
|
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
|
|
Jul 30
|
3 Stocks Estimated To Be Trading At A Discount Of Up To 49.9%
|
|
Jul 28
|
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
|
|
Jul 26
|
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
|
|
Jul 23
|
US High Growth Tech Stocks To Watch In July 2025
|
|
Jul 18
|
The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs
|
|
Jul 10
|
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
|
|
Jul 8
|
Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
|
|
Jun 28
|
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
|
|
Jun 26
|
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
|
|
Jun 25
|
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
|
|
May 27
|
Sector Update: Health Care Stocks Rise Premarket Tuesday
|
|
May 27
|
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
|
|
May 27
|
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer
|
|
May 27
|
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
|
|
May 22
|
Exploring US High Growth Tech Stocks In May 2025
|
|
May 22
|
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
|
|
Apr 5
|
BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA
|
|
Feb 17
|
HRMY or ONC: Which Is the Better Value Stock Right Now?
|